CONSTITUENT REPORT
Camphor
Camphor is a classic monoterpene ketone best known for its penetrating cooling aroma and its long use in topical vapor-rub and external-analgesic products. Public evidence is strongest for identity, sensory-channel pharmacology, and safety: accessible literature supports topical chemesthetic activity through TRP-channel modulation, while toxicology sources consistently warn that ingestion can cause rapid neurologic symptoms and seizures, especially in children. Archive framing should therefore treat camphor as a well-defined aromatic constituent with meaningful topical-sensory relevance and unusually important dose-dependent safety constraints.
Chemical identity and composition
PubChem and NIST identify camphor as C10H16O with the bicyclic bornan-2-one skeleton. Archive oil records place it as a major or secondary marker in rosemary ct. camphor, Dalmatian sage, lavandin grosso, blue tansy, mugwort, and other camphoraceous chemotypes rather than only as a trace constituent.
Aroma and practical use
- Use the recorded camphoraceous, penetrating, cooling, medicinal, woody descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Compare the recorded goal signals with the intended purpose, while keeping model assumptions separate from observed study outcomes.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2005 J Neurosci study reported that camphor activated TRPV1 less potently than capsaicin but produced faster and more complete desensitization.
The PMC full text and linked journal summary describe camphor as a vanilloid-independent TRPV1 modulator with strong desensitizing behavior, a plausible basis for topical counterirritant use.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2007 British Journal of Pharmacology paper found camphor among the monoterpenes that activate TRPV3, with receptor pharmacology centered on thermosensory signaling in transfected cells and oocytes.
The article positions camphor as part of a broader monoterpenoid TRPV3 agonist structure-activity set relevant to skin sensation research.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2006 poison-center guideline and later clinical reviews describe camphor ingestion as rapidly toxic, with seizures and severe neurologic effects possible after relatively small exposures.
Public abstracts describe roughly 10,000 annual ingestion exposures in older U.S. poison-center data and emphasize the fast onset of GI and neurologic toxicity after ingestion.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
How it contributes to goal calculations
Model markers guide the formulation score. They are separate from the source findings above.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedFDA OTC Monograph M017 lists camphor as an external-analgesic active at 0.1-3% and as a counterirritant above 3% to 11%, confirming recognized topical use but also bounded concentration windows.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Poisoning literature consistently warns that ingestion can trigger rapid neurologic toxicity including seizures, apnea, delirium, and coma, with children at particular risk.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
This record should not be used to justify oral-use claims; the most robust public safety signal for camphor is ingestion hazard rather than systemic benefit.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
1,8-cineoleAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read 1,8-cineole report →1,8-cineoleAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
animal · effect
No source citation attached.
Read 1,8-cineole report →How the effects were investigated
TRPV1 activation followed by rapid desensitization
PMC-indexed sensory literature reports that camphor activates TRPV1 relatively weakly but desensitizes it rapidly and substantially, helping explain its topical cooling and analgesic reputation.
This experimental finding does not establish benefit, dose or safety in people using this blend.
TRPV3 agonism in skin-linked sensory systems
A TRPV3 agonist study identified camphor as a monoterpenoid activator of TRPV3, supporting a skin-sensation mechanism rather than a medical efficacy claim.
This experimental finding does not establish benefit, dose or safety in people using this blend.
TRPA1 inhibition and cooling-pathway modulation
Later TRP-channel work describes analgesic effects for camphor partly through inhibition of TRPA1 and interaction with cooling-sensitive pathways.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- This pass did not verify a high-quality human trial on isolated camphor alone for pain, itch, or respiratory outcomes.
- The camphor literature is split across racemic, natural, and stereoisomer-specific forms; this archive record uses the general constituent identity rather than assigning every finding to one enantiomer.
- Most benefit-facing literature is mechanistic or mixed-formulation research, while the clearest constituent-specific human evidence remains toxicology rather than efficacy.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.